| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Pharmacology, University of California, San Diego, La Jolla, CA.
Address correspondence and reprint requests to Dr. Palmer Taylor, Department of Pharmacology, 0636; University of California, San Diego, La Jolla, CA 92093.
Abstract.
Acetylcholinesterase (AChE) inhibitors were first administered in Europe to human subjects in the 1860s, and synthetic derivatives of the natural alkaloid inhibitors were developed in the 1930s to modulate peripheral cholinergic function. However, only within the last decade have these agents been systematically studied for therapy of central cholinergic deficits. This time interval parallels the cloning of the gene and determination of the structure of the target molecule, AChE. Because AChE in mammals is encoded by a single gene and the portion of the gene encoding the catalytic domain is invariant, selectivity of action can be achieved only by altering parameters of disposition and pharmacokinetics of action of the inhibitor rather than its specificity for particular AChE isozymes in various regions of the CNS. This article describes the mechanism of action of short-acting, carbamoylating, and phosphorylating inhibitors of cholinesterase and suggests possible strategies for enhancing therapeutic efficacy.
This article has been cited by other articles:
|
|
 |
|
  B R Thanvi and T C N Lo Update on myasthenia gravis Postgrad. Med. J., December 1, 2004; 80(950): 690 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Kothari Myasthenia Gravis J Am Osteopath Assoc, September 1, 2004; 104(9): 377 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Madhavan, W. J. Freed, V. Anantharam, and A. G. Kanthasamy 5-Hydroxytryptamine 1A Receptor Activation Protects against N-Methyl-D-aspartate-Induced Apoptotic Cell Death in Striatal and Mesencephalic Cultures J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Dunah and D. G. Standaert Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane J. Neurosci., August 1, 2001; 21(15): 5546 - 5558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kraut, H. Goff, R. K. Pai, N. A. Hosea, I. Silman, J. L. Sussman, P. Taylor, and J. G. Voet Inactivation Studies of Acetylcholinesterase with Phenylmethylsulfonyl Fluoride Mol. Pharmacol., June 1, 2000; 57(6): 1243 - 1248. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Konitsiotis, P. J. Blanchet, L. Verhagen, E. Lamers, and T. N. Chase AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys Neurology, April 25, 2000; 54(8): 1589 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Mazurek, P. P. De Deyn, R. Mayeux, and M. Sano Treatment of Alzheimer's Disease N. Engl. J. Med., March 16, 2000; 342(11): 821 - 822. [Full Text]
|
|
|
|
|
|
A. W. Dunah, Y. Wang, R. P. Yasuda, K. Kameyama, R. L. Huganir, B. B. Wolfe, and D. G. Standaert Alterations in Subunit Expression, Composition, and Phosphorylation of Striatal N-Methyl-D-Aspartate Glutamate Receptors in a Rat 6-Hydroxydopamine Model of Parkinson's Disease Mol. Pharmacol., February 1, 2000; 57(2): 342 - 352. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
